For Patients with Advanced NSCLC

EA5162 Available Through ECOG-ACRIN Cancer Research Group

Phase II Study of AZD9291 (Osimertinib) in Advanced NSCLC Patients with Exon 20 Insertion Mutations in EGFR

**Patient Population**

See Section 3.0 for Complete Eligibility Details

- Must have a pathologically-confirmed diagnosis of NSCLC; must have measurable disease per protocol
- Must have advanced disease—either stage IV disease, stage IIIb disease not amenable to definitive multimodality therapy, or recurrent disease after a prior diagnosis of stage I-IIII disease (AJCC/IASLC 7th ed.)
- An EGFR exon 20 insertion mutation must be detected in the tumor tissue
- Must have previously received at least 1 line of therapy for their advanced lung cancer (no restrictions on maximum number of prior therapies allowed)
- Must not have previously received osimertinib or prior treatment with therapies targeting PDL1, PD1, or CTLA4
- Age ≥ 18 years, ECOG PS ≤ 1, and adequate lab values
- No clinically active or symptomatic interstitial lung disease/interstitial pneumonitis, or a history of clinically significant interstitial lung disease/radiation pneumonitis
- May not have had radiation to the lung fields within 28 days of starting treatment; for patients receiving palliative radiation to a site where the field includes the lungs, radiation must be completed at least 2 weeks before starting treatment; for palliative radiation to all other sites, at least 7 days must have elapsed prior to starting treatment; at least 180 days must have elapsed prior to starting treatment for radiation given with curative intent
- No clinically symptomatic brain metastases or leptomeningeal disease
- Certain cardiac criteria are not permitted (see protocol)
- No second, clinically active, cancer
- No uncontrolled intercurrent illness (see protocol)
- No history of hypersensitivity to active/inactive excipients of AZD9291/drugs with a similar chemical structure/class
- Certain concomitant medications/treatments not permitted per protocol

**Treatment Plan**

See Section 5.0 for Complete Treatment Details

- AZD9291 (osimertinib) administered at a dose of 160 mg by mouth once daily on days 1-21 of a 21-day cycle
- AZD9291 should be taken at the same time every day (+/- 4 hours; either in the AM or PM), with or without food
- Treatment will be given without interruption, unless interruptions are required to manage treatment-related side effects
- Missed doses will not be taken later
- Patients should continue on treatment with AZD9291 until RECIST 1.1 defined progression or until treatment discontinuation criteria (per protocol) are met
- Patients may continue to receive AZD9291 beyond RECIST 1.1 defined progression as long as they are continuing to show clinical benefit as judged by the investigator (i.e., there is no maximum duration of treatment)

**Study Chair:**
Zofia Piotrowska, M.D., M.H.S.

**Co-Chair:**
Lecia Sequist, M.D., M.P.H.

**Please Enroll Your Eligible Patients!**
EA5162 Available Through ECOG-ACRIN Cancer Research Group

Phase II Study of AZD9291 (Osimertinib) in Advanced NSCLC Patients with Exon 20 Insertion Mutations in EGFR

Schema

```
REGISTRATION
```

```
Osimertinib 160mg PO daily without interruption
```

```
FOLLOW-UP
```

Cycle = 3 weeks (21 days)
Accrual = 20 patients

1. Until disease progression or unacceptable toxicities.
2. Restaging scans every 2 cycles (6 weeks).
3. Patients will be followed for 5 years from registration.

The primary endpoint is best objective response per RECIST 1.1, with confirmation of response required.